Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly and insitro team up to develop AI-powered siRNA metabolic drugs
Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and smaller biotechs.
Lilly, Insitro Ink Unique AI Deal, Eye Novel Treatments for Metabolic Diseases
In a departure from most deals, startup insitro will in-license Lilly’s delivery technology for its investigational liver-targeted siRNA therapies. The pharma will be eligible for milestones and royalties down the line.
Eli Lilly delivers for AI-powered insitro to clear siRNA molecules’ path to clinic
Insitro has teamed up with Eli Lilly to help power programs into the clinic, tapping the Big Pharma for an option on technology to deliver siRNA molecules it discovered using its machine learning platform.
Eli Lilly, Insitro ink a new kind of AI drug development deal
Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases.
Lilly partners with AI specialist Insitro to develop metabolic medicines
The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.
STAT
1d
Prime Medicine lays off workers as it trims pipeline
Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...
The Pharma Letter
10h
Machine learning at heart of insitro and Lilly link-up
Insitro has signed three strategic agreements with Eli Lilly aimed at advancing treatments for metabolic diseases like MASLD, ...
labiotech
21h
12 biotech unicorns revolutionizing the future of healthcare
Take a closer look at 12 biotech unicorns, with a worth of more than $1 billion, that are trying to revolutionize the ...
pharmaphorum
3y
BMS joins forces with insitro to develop neurodegenerative treatments
insitro
uses machine-learning technology to discover novel drug targets and patient segments. Since its inception in 2018, the company has brought on several high-profile partners and investors.
ENDPOINTS NEWS
1d
AI biotech insitro partners with Lilly on metabolic disease drugs
If all goes according to plan, insitro could finally start testing its first drug in clinical trials in 2026, eight years ...
24/7 Wall St
2mon
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 593.90% and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Eli Lilly and Company
Artificial intelligence
Metabolic disorder
MASLD
Feedback